Nasdaq:US$14.84 (-0.59) | HKEX:HK$23.65 (-0.10) | AIM:£2.19 (-0.01)
Search Result
Previous Article   |   Next Article
Scientific Publications | 3 Nov 2021

NANETS 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors